Evidence mapPaperPMID 40539460Full record

ReviewOncology reports2025

Comprehensive

Fernán Gómez-Valenzuela, Ian Silva, Ignacio N Retamal, Benjamín García-Bloj, Tomás De Mayo Glasser, Matías Muñoz-Medel, Alex Gómez, Cristopher San Martín, Carolina Sánchez, Felipe Pinto and 10 more

Abstract readReview
In one paragraph

Review in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fernán Gómez-ValenzuelaPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Ian SilvaPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Ignacio N RetamalPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Benjamín García-BlojPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Tomás De Mayo GlasserPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Matías Muñoz-MedelPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Alex GómezPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Cristopher San MartínPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Carolina SánchezPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Felipe PintoPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Paola AravenaPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Andrea C SabioncelloPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Marcelo Garrido VillanuevaPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Fernando Sigler ChávezPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Ignacio CorvalánPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Henry BarriosPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
José M ErpelPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Patricio A ManquePrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Juan A GodoyPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.
Marcelo GarridoPrecision Oncology Center, Universidad Mayor, Las Condes, Santiago 7500000, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer, a prevalent and fatal form of cancer worldwide, is manifested at different age ranges during the lifespan. Approximately one‑third of newly diagnosed gastric cancer cases are early‑onset gastric cancer (EO‑GC), which affects individuals under the age of 50 years. EO‑GC tends to be more aggressive than late‑onset gastric cancer (L‑GC), with a faster and multifocal disease progression. Furthermore, EO‑GC is associated with early metastatic disease. Recent research has underscored the need for a deeper understanding of EO‑GC that promotes therapeutic approaches specific to EO‑GC. The present study determined the main transcriptomic differences between EO‑GC and L‑GC. Transcriptomic expression data from The Cancer Genome Atlas‑Stomach Adenocarcinoma were explored to elucidate whether age is associated with a specific genomic expression pattern and is associated with gastric cancer. Subsequently, a differential gene expression analysis of the EO‑GC vs. L‑GC groups was performed, providing new insights into EO‑GC gene expression characteristics and their association with survival outcomes. Furthermore, the study focused on whether the influence of representative gene expression in EO‑GC cases (

Indexed as

AdenocarcinomaBiomarkers, TumorStomach NeoplasmsAge of OnsetComputer SimulationDisease ProgressionDNA MethylationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTranscriptomeBiomarkers, Tumordifferentially expressed geneearly‑onset gastric cancergastric cancer

Identifiers

PMID40539460
PMCPMC12199296

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.